Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

D-578 demonstrates antidepressant and anti-PTSD-like effects in vivo

Sep. 19, 2019

Waking up sleeping Xs

Sep. 19, 2019

Mitochondria differ between cell types

Sep. 19, 2019

Imotope shows promise in EAE model

Sep. 19, 2019

Ra's zilucoplan selected for evaluation in ALS platform trial

Sep. 18, 2019

Antisense Therapeutics reports preliminary phase II data on ATL-1102 in Duchenne muscular dystrophy

Sep. 18, 2019

Preliminary first-in-human data for ATA-188 support continuation of study

Sep. 18, 2019

Life Molecular Imaging opens enrollment for phase II trial of next-generation tau PET tracer PI-2620

Sep. 17, 2019

Neuronascent studies NNI-362 in healthy aged volunteers in first-in-human trial

Sep. 17, 2019

Acceleron ends development of ACE-083 for facioscapulohumeral muscular dystrophy

Sep. 17, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...